Previous 10 | Next 10 |
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and ad...
The big story in the stock market today: Facebook Meta stock . Shares of the tech company fell to levels not seen since the summer of 2020. Even with the pullback in broader markets, Meta Platforms ( NASDAQ:FB ) struggled to reclaim early 2022 prices as uncertainty arose thanks ...
OPKO Health (OPK +5.3%) trades higher following the company's CEO & Chairman bought 150,000 shares at $2.99 - $3.05 worth ~ $460K. For further details see: OPKO Health rises 5% as CEO & Chairman buys 1.5M shares
Opko Health (OPK +5.1%) said Vifor Fresenius Medical Care Renal Pharma launched Rayaldee (extended release calcifediol) in Germany. Rayaldee extended-release capsules are indicated for treating secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease ...
MIAMI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE ® (extended release calcifediol) in Germany, the first launch of RAYALDEE outside the U.S. ...
The U.S. Food and Drug Administration (FDA) recently refused to approve Pfizer 's (NYSE: PFE) and Opko Health 's (NASDAQ: OPK) growth hormone therapy, somatrogon. In this Motley Fool Live video, recorded on Jan. 26 , Motley Fool contributors Keith Speights and Brian ...
Shares of Opko Health (NASDAQ: OPK) were crashing 32.3% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence . The steep decline came after Opko and its partner, Pfizer (NYSE: PFE) , announced after the market clo...
A rough day for the broad market is a downright terrible one for Opko Health (NASDAQ: OPK) . Shares of the drug and diagnostics outfit were down by 23% as of 1:22 p.m. ET on Monday following Friday's post-close announcement that a growth-hormone deficiency treatment co-developed wit...
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recom...
TOKYO and MIAMI, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA ® (somatrogon) Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry of Health,...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common ...
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relat...
NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner PR Newswire New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additi...